Dermatitis bullosa caused by the immune checkpoint inhibitor camrelizumab: A case report

doi:10.12998/wjcc.v13.i8.97677

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (15)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-2)

Sum=13

Mar 16, 2025 (publication date) through Dec 4, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Mar 16, 2025; 13(8): 97677
Published online Mar 16, 2025. doi: 10.12998/wjcc.v13.i8.97677

Open in New Tab Full Size Figure Download Figure

Figure 1 Pictures of hand treatment process. A: The 15^th day after immunotherapy; B: The 17^th day after immunotherapy; C: Day 6 of hormone therapy; D: Day 26 of hormone therapy.

Citation: Jiang YJ, Wu L, Yang X, Pu Y, Ning BJ, Peng N, Zhu XJ. Dermatitis bullosa caused by the immune checkpoint inhibitor camrelizumab: A case report. World J Clin Cases 2025; 13(8): 97677
URL: https://www.wjgnet.com/2307-8960/full/v13/i8/97677.htm
DOI: https://dx.doi.org/10.12998/wjcc.v13.i8.97677